Facilitated By

San Antonio Medical Foundation

Combination immunotherapy with Herceptin and the HER2 vaccine E75 in low and intermediate HER2-expressing breast cancer patients to prevent recurrence

Cancer Insight, LLC

Cancer Insight is a Texas-based boutique contract research organization (CRO) dedicated to discovering, developing and testing emerging biotechnologies focused on cancer immunotherapy. Founded by industry pioneer Dr.

Principal Investigator(s)
George Peoples
Funded by
Industry Sponsored
Research Start Date

This study includes patients that have been treated for node-positive (NP) or high-risk node-negative (NN) breast cancer where they are at risk for recurrence (breast cancer coming back); and also because tumor cells show a specific protein called HER2/neu on their cell surfaces. “Node-positive” means that breast cancer has been found in the lymph nodes. “High-risk node-negative” for the purposes of this trial means that breast cancer has not been found in the lymph nodes but that the tumor is not sensitive to hormones which means that a patient may be at an increased risk for recurrence.

Drug Discovery